Exenatide Reconstitution Calculator

Yes. Exenatide (Byetta) was the first FDA-approved GLP-1 receptor agonist, approved in 2005 for type 2 diabetes, built on exendin-4 isolated from Gila monster venom in 1992. A once-weekly microsphere formulation (Bydureon) followed. Obesity indications went to later agents such as liraglutide and semaglutide, not exenatide.

Start at 5 mcg subcutaneously twice daily at mealtimes for 4 weeks, then 10 mcg twice daily (RCT). Once-weekly Bydureon or Bydureon BCise: 2 mg weekly; the 2 mg autoinjector reduced HbA1c by -1.4% versus -1.0% for 10 mcg twice daily over 28 weeks (RCT). Gradual titration is evidence-based: dose escalation cut nausea from 56% to 27% (RCT). Exenatide's approved formulations are injectable only.

Modest, dose-dependent loss. In 30-week placebo-controlled RCTs in type 2 diabetes, 10 mcg twice daily produced -2.8 kg (RCT). A 2026 network meta-analysis found exenatide reduced body weight by -2.97 kg versus placebo, with moderate-certainty evidence (RCT).

Semaglutide wins decisively on weight: -10.98 kg versus -2.97 kg for exenatide in the same network meta-analysis, both moderate certainty (RCT). Glycemic effect is closer: once-weekly exenatide 2 mg reached -1.4% HbA1c. Safety differs: semaglutide carries the strongest GERD pharmacovigilance signal (ROR 3.44-6.93) while exenatide shows an inverse association (ROR 0.60); NAION signals concentrate on semaglutide, with exenatide findings absent or inconsistent.

Yes. Nausea is exenatide's most frequent adverse event, usually mild to moderate and transient (RCT). Escalation prevents most of it: priming from 0.02 mcg/kg three times daily, increasing 0.02 mcg/kg every 3 days, reduced nausea to 27% versus 56% in naive subjects, without loss of glucose lowering (RCT). The weekly formulation reports fewer GI events: 22.7% versus 35.6% with twice-daily dosing.

Human data are absent. In an ex vivo perfused human placenta model, exenatide crossed negligibly, with a fetal-to-maternal ratio of at most 0.017 (ex-vivo). Human teratogenicity is unstudied; clinical practice is to discontinue GLP-1 therapy before or upon confirming pregnancy (practitioner consensus).

Phase 3 evidence says no. Two earlier phase II trials suggested motor benefit, but Exenatide-PD3 (n=231) showed no benefit over placebo, while a parallel trial of lixisenatide slowed motor progression (RCT). One interpretation: participants lacked the insulin desensitization that may mediate benefit (hypothesis). Current phase 3 data do not support off-label exenatide for Parkinson's.

Yes: Byetta requires cold storage. Unopened pens should be kept at 2-8°C; a pen in use may be held at room temperature up to 30 days (practitioner consensus). The weekly Bydureon pen contains PLGA microspheres that need vigorous shaking (>15 seconds) to resuspend before injection; depot-related injection-site swelling can persist for weeks.